Pegloticase Injection bulk supplier for pharma manufacturers

Pegloticase Injection 8 mg/1.2 mL vial Suppliers & Bulk Manufacturers

Available Forms: Injectable (IV solution)

Available Strengths: 8 mg/1.2 mL vial

Reference Brands: Krystexxa (US)

Category: Arthritis

Pegloticase is an intravenous uricase enzyme for severe chronic gout that has not responded to other treatment. It breaks down uric acid quickly, dissolving deposits (tophi). It is given every two weeks, often with methotrexate to prevent antibodies, and requires G6PD testing first. It is made by Amgen as Krystexxa. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Pegloticase Injection? List it or send an offer →

Product Description: Pegloticase injectable is approved in the US for the treatment of severe, refractory gout unresponsive to conventional therapies. In the EU, it is not widely approved; primarily marketed in the US under the brand Krystexxa (by Horizon Therapeutics). Regulatory dossiers demonstrate safety, efficacy, and manufacturing quality supported by clinical trial data. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory submissions, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for pegloticase, ensuring adherence to European and US standards for safe, effective management of refractory gout, helping clients navigate complex regulatory landscapes seamlessly.

How Pegloticase Injection is supplied today, and licensing ahead of patent expiry

Pegloticase Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Pegloticase Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Pegloticase Injection supply →

Back to Listing

Frequently Asked Questions

8 mg by intravenous infusion over at least 2 hours every 2 weeks, with premedication and usually with weekly methotrexate.

A rise above 6 mg/dl suggests antibodies have formed, which increases the risk of infusion reactions, so treatment is stopped.

Pegloticase can cause haemolysis and methaemoglobinaemia in people with G6PD deficiency.

Krystexxa (Pegloticase) is developed and sold by Amgen (formerly Horizon Therapeutics). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.